Therapeutic strategies for targeting mononuclear phagocytes in cancer.
The initiation and progression of cancer is dependent on factors both intrinsic and extrinsic to the malignant cells. Stromal, vascular endothelial, and inflammatory cells are the principal normal populations that support tumors by supplying factors and nutrients. The mononuclear phagocyte lineage, which includes monocytes, macrophages, and dendritic cells is of particular clinical interest because lineage members can enhance tumor angiogenesis and metastasis, or alternately contribute to tumor destruction. Thus therapies that regulate these cells represent an innovative approach for improving patient survival in childhood cancer.
Dickens
David S
DS
Pediatric Hematology/Oncology, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
Jubinsky
Paul T
PT
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D012157:Mononuclear Phagocyte System / Q000187:drug effects* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents